All in the blood: New way to detect drug resistance in ovarian cancer patients

Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients who are likely to become resistant to PARP inhibitors (PARPi), a key therapy used to treat ovarian and breast cancers in Australia.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup